BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36330569)

  • 21. Comparison Between
    Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
    Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
    Nitsch S; Hakenberg OW; Heuschkel M; Dräger D; Hildebrandt G; Krause BJ; Schwarzenböck SM
    J Nucl Med; 2016 Oct; 57(Suppl 3):38S-42S. PubMed ID: 27694169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
    Schiavina R; Scattoni V; Castellucci P; Picchio M; Corti B; Briganti A; Franceschelli A; Sanguedolce F; Bertaccini A; Farsad M; Giovacchini G; Fanti S; Grigioni WF; Fazio F; Montorsi F; Rigatti P; Martorana G
    Eur Urol; 2008 Aug; 54(2):392-401. PubMed ID: 18456393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. "Real-world" evaluation of
    Niziers V; Boissier R; Borchiellini D; Deville JL; Khoury C; Durand M; Toledano H; Albert T; Branger N; Bandelier Q; Ouvrier MJ; Gabriel S; Hoch B; Gross E; Walz J; Brenot-Rossi I; Pignot G
    Urol Oncol; 2020 Jan; 38(1):2.e1-2.e9. PubMed ID: 31447087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
    Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
    Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
    Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
    Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY; Lee MT; Lin CL; Kao CH
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
    Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
    Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
    Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
    Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
    World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
    Hermsen R; Wedick EBC; Vinken MJM; van Kalmthout LWM; Küsters-Vandevelde HVN; Wijers CHW; Somford DM; van Basten JA
    Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3929-3937. PubMed ID: 35543733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer.
    Husarik DB; Miralbell R; Dubs M; John H; Giger OT; Gelet A; Cservenyàk T; Hany TF
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):253-63. PubMed ID: 17926036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
    García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
    Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of PET-CT with
    Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A
    Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.
    Rinnab L; Mottaghy FM; Blumstein NM; Reske SN; Hautmann RE; Hohl K; Möller P; Wiegel T; Kuefer R; Gschwend JE
    BJU Int; 2007 Oct; 100(4):786-93. PubMed ID: 17822459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
    Picchio M; Spinapolice EG; Fallanca F; Crivellaro C; Giovacchini G; Gianolli L; Messa C
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):13-26. PubMed ID: 21932120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.